Pioneering research on biomolecular
diffusion in nanofluidics, Abionic has developed the
abioSCOPE, an in-vitro platform performing quantitative diagnostic testing. Its first
application products: abioKIT Total IgE (1 test in 5min) and abioKIT Aeroallergens (6
tests in 12 min) are now available in the POC diagnostic market in Europe, and in 2016
in the U.S. Venture Valuation (VV) interviewed the CEO, Dr. Nicolas Durand.